Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Net Income (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Net Income for 14 consecutive years, with -$102.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income fell 100.63% year-over-year to -$102.0, compared with a TTM value of -$404497.0 through Oct 2025, up 47.98%, and an annual FY2025 reading of -$100463.0, up 87.08% over the prior year.
  • Net Income was -$102.0 for Q4 2025 at Pharma-Bio Serv, up from -$309098.0 in the prior quarter.
  • Across five years, Net Income topped out at $2.3 million in Q3 2021 and bottomed at -$4.9 million in Q4 2021.
  • Average Net Income over 5 years is -$49167.5, with a median of $123577.5 recorded in 2022.
  • Peak annual rise in Net Income hit 228.72% in 2021, while the deepest fall reached 3475.66% in 2021.
  • Year by year, Net Income stood at -$4.9 million in 2021, then surged by 104.74% to $231044.0 in 2022, then crashed by 122.11% to -$51078.0 in 2023, then skyrocketed by 131.54% to $16111.0 in 2024, then plummeted by 100.63% to -$102.0 in 2025.
  • Business Quant data shows Net Income for PBSV at -$102.0 in Q4 2025, -$309098.0 in Q3 2025, and -$103833.0 in Q2 2025.